Lisa Krinsky resigned as president, and Arnold Hantman as its chief executive. On Dec. 19, Gerald Seifer, director of legal affairs quit.
" Krinsky, who the company refers to as a medical doctor, is a graduate of Spartan Medical School in St. Lucia and not a
licensed doctor. Krinsky and former director of legal affairs Gerald Seifer, who isn’t a lawyer, share a $15 million home they
purchased last year. Seifer resigned Dec. 19 after an investigation found he engaged in inappropriate'' behavior with trial subjects, the<br />company said. Prior to his resignation, Seifer was placed on 30 days paid leave after a report from two law firms hired by<br />SFBC's board found that a witness heard Seifer threaten to have research subjects deported, the company said.<br /> Hantman, referred to in company SEC filings as a CPA, is not licensed as a certified public accountant. Jack Levine, who<br />previously was lead director, was elected chairman of the board of directors, SFBC said. Hantman, Seifer and Krinsky were among SFBC's founders."<br /><br />A team of investigative reporters at Bloomberg News provide a reality check on the seedy side of for-profit clinical trial companies that have been operating with impunity until Bloomberg's expose. Big Pharma's Shameful Secret (see: https://ahrp.org/infomail/05/11/03.php )<br /><br /> <br />Contact: Vera Hassner Sharav<br />veracare@ahrp.org<br /> <br />BLOOMBERG NEWS<br /> SFBC Loses Two Top Officials Amid U.S. Senate Inquiry <br />2006-01-03 08:50 (New York)<br />By Kerry Dooley Young and David Evans<br /><br /> Jan. 3 (Bloomberg) -- SFBC International Inc.'s two top officials quit just before they were to be interviewed by Senate<br />investigators probing the company's management of the largest private clinical trials center in North America. Jeffrey<br />McMullen was named chief executive officer.<br /><br /> Lisa Krinsky, 43, resigned as president and chairman and Arnold Hantman, 69, retired as chief executive, the Miami-based<br />company said today in a statement on Business Wire. Krinsky was to meet with Sen. Charles Grassley's staff Jan. 11 as part of<br />Grassley's inquiry into drug trial safety issues. No date was set for a meeting Grassley sought with Hantman.<br /> Grassley, the Senate finance committee chairman, began his review after Bloomberg News reported in November on conflicts of<br />interest and lax oversight in the industry. The SBFC management changes come as it struggles to regain investor confidence after<br />Miami officials forced SFBC to remove half the beds in its main testing center because of safety issues, Canadian health<br />officials began probing a tuberculosis outbreak in a Montreal drug trial, and SFBC hired investment banking advisers to<br />explore strategic alternatives.”
We recognize the challenges facing SFBC's Miami facility, and we believe we have the management team and structure in<br />place to meet these challenges and reestablish SFBC's leadership position in the drug development services industry,'' McMullen<br />said in the statement.<br /><br /> SFBC shares fell 38 cents, or 2.3 percent, to $16.01 on Dec. 30 in Nasdaq Stock Market composite trading. SFBC shares<br />have lost 61 percent of their value since Nov. 1, the day before Bloomberg News reported that bioethicist said the company's<br />consent process inadequately warned drug trial participants of the risks of injury and death.<br /><br /> Krinsky Background<br /><br /> Krinsky, who the company refers to as a medical doctor, is a graduate of Spartan Medical School in St. Lucia and not a<br />licensed doctor. Krinsky and former director of legal affairs Gerald Seifer, who isn't a lawyer, share a $15 million home they<br />purchased last year.<br /> Seifer resigned Dec. 19 after an investigation found he engaged ininappropriate” behavior with trial subjects, the
company said. Prior to his resignation, Seifer was placed on 30 days paid leave after a report from two law firms hired by
SFBC’s board found that a witness heard Seifer threaten to have research subjects deported, the company said.
Hantman, referred to in company SEC filings as a CPA, is not licensed as a certified public accountant. Jack Levine, who
previously was lead director, was elected chairman of the board of directors, SFBC said.
Hantman, Seifer and Krinsky were among SFBC’s founders.
McMullen
McMullen, 43, is now president and CEO of SFBC’s Pharmanet unit, a clinical trial company purchased in December. His
background includes time spent as a member of the senior management team at Corning Pharmaceutical Services, now Covance
Inc., another organizer of medical studies.
McMullen’s 13 years at Covance include a range of operational, business development and sales and marketing roles,
the statement said. SFBC updated its earnings guidance to reflect the separation agreements with Krinsky and Hantman. The company will
take one-time, pretax charges of $3.83 million, or about 17 cents a share net of tax effect, in the fourth quarter of 2005.
SFBC’s new guidance for 2005 is about $1.39 to $1.44 in GAAP earnings per share.
Grassley, an Iowa Republican, has also requested documents from U.S. regulators on inspections of SFBC. Last month,
Grassley said Inspector General Daniel Levinson should quickly compile a list of recommendations his office has made since 1995
and determine whether the appropriate federal agencies are heeding them.
Law Firms’ Report
The company said last month that it had sent Grassley a copy of a report by two law firms SFBC hired to conduct an
independent review of allegations in the Bloomberg report. The resulting report from Winston & Strawn, based in Chicago, and
Tew Cardenas of Miami “exonerated” the company, SFBC said.
The review found that a witness heard Seifer, then SFBC’s vice president of legal affairs, threaten to have research
subjects deported. Seifer, a 10-year employee, was placed on 30 days paid leave after the report, and the company said Dec. 19
that he resigned.
–With reporting by Michael Smith in Rio De Janiero. Editor: Gale (rtg)
To contact the reporters on this story:
Kerry Dooley Young in Washington (1) (202) 624-1936 or
kdooley@bloomberg.net;
David Evans in Los Angeles (1) (323) 782-4241 or
davidevans@bloomberg.net
To contact the editor responsible for this story:
Robert Simison at (1) (202) 624-1812 or
rsimison@bloomberg.net.
FAIR USE NOTICE: This may contain copyrighted (© ) material the use of which has not always been specifically authorized by the copyright owner. Such material is made available for educational purposes, to advance understanding of human rights, democracy, scientific, moral, ethical, and social justice issues, etc. It is believed that this constitutes a ‘fair use’ of any such copyrighted material as provided for in Title 17 U.S.C. section 107 of the US Copyright Law. This material is distributed without profit.